Regulation and therapy: the role of ferroptosis in DLBCL
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of B-cell non-Hodgkin’s lymphoma (NHL), up to 30%–40% of patients will relapse and 10%–15% of patients have primary refractory disease, so exploring new treatment options is necessary. Ferroptosis is a non-apoptotic cell death mode dis...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1458412/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841558709946286080 |
|---|---|
| author | Yifan Wang Yifan Wang Zhengmei He Zhengmei He Xinyu Dong Xinyu Dong Yiming Yao Yiming Yao Qiuni Chen Qiuni Chen Yuye Shi Yuye Shi Yuan Deng Yuan Deng Quane Zhang Quane Zhang Liang Yu Liang Yu Liang Yu Chunling Wang Chunling Wang Chunling Wang |
| author_facet | Yifan Wang Yifan Wang Zhengmei He Zhengmei He Xinyu Dong Xinyu Dong Yiming Yao Yiming Yao Qiuni Chen Qiuni Chen Yuye Shi Yuye Shi Yuan Deng Yuan Deng Quane Zhang Quane Zhang Liang Yu Liang Yu Liang Yu Chunling Wang Chunling Wang Chunling Wang |
| author_sort | Yifan Wang |
| collection | DOAJ |
| description | Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of B-cell non-Hodgkin’s lymphoma (NHL), up to 30%–40% of patients will relapse and 10%–15% of patients have primary refractory disease, so exploring new treatment options is necessary. Ferroptosis is a non-apoptotic cell death mode discovered in recent years. Its occurrence pathway plays an essential impact on the therapeutic effect of tumors. Numerous studies have shown that modulating critical factors in the ferroptosis pathway can influence the growth of tumor cells in hematological malignancies including DLBCL. This review highlights recent advances in ferroptosis-related genes (FRGs), including STAT3, Nrf2, and ZEB1, and focuses on the clinical potential of ferroptosis inducers such as IKE, α-KG, DMF, and APR-246, which are currently being explored in clinical studies for their therapeutic effects in DLBCL. Correlational studies provide a novel idea for the research and treatment of ferroptosis in DLBCL and other hematological malignancies and lay a solid foundation for future studies. |
| format | Article |
| id | doaj-art-9186b05ce9ff4cba982315d5eeef43e4 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-9186b05ce9ff4cba982315d5eeef43e42025-01-06T06:59:00ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.14584121458412Regulation and therapy: the role of ferroptosis in DLBCLYifan Wang0Yifan Wang1Zhengmei He2Zhengmei He3Xinyu Dong4Xinyu Dong5Yiming Yao6Yiming Yao7Qiuni Chen8Qiuni Chen9Yuye Shi10Yuye Shi11Yuan Deng12Yuan Deng13Quane Zhang14Quane Zhang15Liang Yu16Liang Yu17Liang Yu18Chunling Wang19Chunling Wang20Chunling Wang21Department of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, ChinaNorthern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, ChinaNorthern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, ChinaNorthern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Huaian Clinical College of Xuzhou Medical University, Huai’an, ChinaNorthern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Huaian Clinical College of Xuzhou Medical University, Huai’an, ChinaDepartment of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, ChinaNorthern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, ChinaNorthern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, ChinaNorthern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, ChinaNorthern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, ChinaNorthern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Huaian Clinical College of Xuzhou Medical University, Huai’an, ChinaDepartment of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, ChinaNorthern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Huaian Clinical College of Xuzhou Medical University, Huai’an, ChinaDiffuse large B-cell lymphoma (DLBCL) is the most common subtype of B-cell non-Hodgkin’s lymphoma (NHL), up to 30%–40% of patients will relapse and 10%–15% of patients have primary refractory disease, so exploring new treatment options is necessary. Ferroptosis is a non-apoptotic cell death mode discovered in recent years. Its occurrence pathway plays an essential impact on the therapeutic effect of tumors. Numerous studies have shown that modulating critical factors in the ferroptosis pathway can influence the growth of tumor cells in hematological malignancies including DLBCL. This review highlights recent advances in ferroptosis-related genes (FRGs), including STAT3, Nrf2, and ZEB1, and focuses on the clinical potential of ferroptosis inducers such as IKE, α-KG, DMF, and APR-246, which are currently being explored in clinical studies for their therapeutic effects in DLBCL. Correlational studies provide a novel idea for the research and treatment of ferroptosis in DLBCL and other hematological malignancies and lay a solid foundation for future studies.https://www.frontiersin.org/articles/10.3389/fphar.2024.1458412/fullferroptosisSTAT3Nfr2ZEB1IKEα-KG |
| spellingShingle | Yifan Wang Yifan Wang Zhengmei He Zhengmei He Xinyu Dong Xinyu Dong Yiming Yao Yiming Yao Qiuni Chen Qiuni Chen Yuye Shi Yuye Shi Yuan Deng Yuan Deng Quane Zhang Quane Zhang Liang Yu Liang Yu Liang Yu Chunling Wang Chunling Wang Chunling Wang Regulation and therapy: the role of ferroptosis in DLBCL Frontiers in Pharmacology ferroptosis STAT3 Nfr2 ZEB1 IKE α-KG |
| title | Regulation and therapy: the role of ferroptosis in DLBCL |
| title_full | Regulation and therapy: the role of ferroptosis in DLBCL |
| title_fullStr | Regulation and therapy: the role of ferroptosis in DLBCL |
| title_full_unstemmed | Regulation and therapy: the role of ferroptosis in DLBCL |
| title_short | Regulation and therapy: the role of ferroptosis in DLBCL |
| title_sort | regulation and therapy the role of ferroptosis in dlbcl |
| topic | ferroptosis STAT3 Nfr2 ZEB1 IKE α-KG |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1458412/full |
| work_keys_str_mv | AT yifanwang regulationandtherapytheroleofferroptosisindlbcl AT yifanwang regulationandtherapytheroleofferroptosisindlbcl AT zhengmeihe regulationandtherapytheroleofferroptosisindlbcl AT zhengmeihe regulationandtherapytheroleofferroptosisindlbcl AT xinyudong regulationandtherapytheroleofferroptosisindlbcl AT xinyudong regulationandtherapytheroleofferroptosisindlbcl AT yimingyao regulationandtherapytheroleofferroptosisindlbcl AT yimingyao regulationandtherapytheroleofferroptosisindlbcl AT qiunichen regulationandtherapytheroleofferroptosisindlbcl AT qiunichen regulationandtherapytheroleofferroptosisindlbcl AT yuyeshi regulationandtherapytheroleofferroptosisindlbcl AT yuyeshi regulationandtherapytheroleofferroptosisindlbcl AT yuandeng regulationandtherapytheroleofferroptosisindlbcl AT yuandeng regulationandtherapytheroleofferroptosisindlbcl AT quanezhang regulationandtherapytheroleofferroptosisindlbcl AT quanezhang regulationandtherapytheroleofferroptosisindlbcl AT liangyu regulationandtherapytheroleofferroptosisindlbcl AT liangyu regulationandtherapytheroleofferroptosisindlbcl AT liangyu regulationandtherapytheroleofferroptosisindlbcl AT chunlingwang regulationandtherapytheroleofferroptosisindlbcl AT chunlingwang regulationandtherapytheroleofferroptosisindlbcl AT chunlingwang regulationandtherapytheroleofferroptosisindlbcl |